Silver Book Fact

Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.

Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al. Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis. BMC Geriatrics. 2003; 3(6). http://www.biomedcentral.com/1471-2318/3/6

Reference

Title
Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis
Publication
BMC Geriatrics
Publication Date
2003
Authors
Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al.
Volume & Issue
Volume 3, Issue 6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicaid costs for people with the disease would be…  
  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease
     
  • Medicaid Costs, Slowed Progression